Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The value of circulating microRNAs for early diagnosis of B-cell lymphoma: A case-control study on historical samples

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Maysaa Abdulla
  • Peter Hollander
  • Tatjana Pandzic
  • Larry Mansouri
  • Susanne Bram Ednersson
  • Per-Ola Andersson
  • Magnus Hultdin
  • Maja Fors
  • Martin Erlanson
  • Sofie Degerman
  • Helga Munch Petersen
  • Fazila Asmar
  • Kirsten Grønbaek
  • Gunilla Enblad
  • Lucia Cavelier
  • Richard Rosenquist
  • Rose-Marie Amini
Vis graf over relationer

The tumor cells in diffuse large B-cell lymphomas (DLBCL) are considered to originate from germinal center derived B-cells (GCB) or activated B-cells (ABC). Gene expression profiling (GEP) is preferably used to determine the cell of origin (COO). However, GEP is not widely applied in clinical practice and consequently, several algorithms based on immunohistochemistry (IHC) have been developed. Our aim was to evaluate the concordance of COO assignment between the Lymph2Cx GEP assay and the IHC-based Hans algorithm, to decide which model is the best survival predictor. Both GEP and IHC were performed in 359 homogenously treated Swedish and Danish DLBCL patients, in a retrospective multicenter cohort. The overall concordance between GEP and IHC algorithm was 72%; GEP classified 85% of cases assigned as GCB by IHC, as GCB, while 58% classified as non-GCB by IHC, were categorized as ABC by GEP. There were significant survival differences (overall survival and progression-free survival) if cases were classified by GEP, whereas if cases were categorized by IHC only progression-free survival differed significantly. Importantly, patients assigned as non-GCB/ABC both by IHC and GEP had the worst prognosis, which was also significant in multivariate analyses. Double expression of MYC and BCL2 was more common in ABC cases and was associated with a dismal outcome. In conclusion, to determine COO both by IHC and GEP is the strongest outcome predictor to identify DLBCL patients with the worst outcome.

OriginalsprogEngelsk
TidsskriftAmerican Journal of Hematology
Vol/bind95
Udgave nummer1
Sider (fra-til)57-67
Antal sider11
ISSN0361-8609
DOI
StatusUdgivet - jan. 2019

Bibliografisk note

© 2019 The Authors. American Journal of Hematology published by Wiley Periodicals, Inc.

ID: 59261263